Daiichi Sankyo and AstraZeneca have received approval from China’s National Medical Products Administration (NMPA) for ...

China NMPA approves Daiichi Sankyo & AstraZeneca’s Datroway for patients with previously treated metastatic HR positive, HER2 negative breast cancer: Tokyo Tuesday, August 26, 2 ...

We recently published 11 Best Cancer Stocks to Buy Right Now. AstraZeneca PLC stands third among them. AstraZeneca PLC (NASDAQ:AZN), headquartered in Cambridge, England, is a leading global ...

During a live event, Kit Yu Lu, MD, discussed data on antibody-drug conjugates in HR+, HER2- breast cancer including the TROPiCS-02 trial.

Daiichi Sankyo & AstraZeneca’s Enhertu gets Japanese approval for patients with HER2 low or HER2 ultralow metastatic breast cancer following at least one endocrine therapy ...

In January 2025, the FDA approved AZN and Daiichi’s second ADC drug, Datroway, for treating unresectable or metastatic ...

"I firmly believe China holds both tremendous growth potential and global strategic importance," Michio Hayashi, who was appointed Daiichi Sankyo China president in April, told Yicai in an exclusive ...

Patritumab deruxtecan is a specifically engineered HER3 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being developed jointly by Daiichi Sankyo and Merck ...

BC, AOCNP, discusses current ADCs in breast, bladder, and lung cancer and highlights promising agents in development.

The agency said it had become aware of more reports of serious adverse events, leading center director Vinay Prasad to ...

An $885M deal with BeOne Medicine gives the pharma financier rights to a revenue stream from global sales of Imdelltra, which ...